Gates Foundation Backs Indian COVID-19 Vaccine Producer

With Gates’ funding, Serum plans to manufacture 100 million doses of Oxford University’s vaccine for poor countries at a cost of $3 or less per dose. A separate deal between Serum and AstraZeneca aims to produce a billion doses of Oxford’s licensed vaccine for low- and middle-income countries. While still not approved, Oxford’s vaccine yielded encouraging results on phase 1 and 2 clinical trials with only mild side effects including headaches and a mild fever.